1. Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial
- Author
-
Faisal Aziz, Norbert J. Tripolt, Peter N. Pferschy, Ewald Kolesnik, Harald Mangge, Pero Curcic, Markus Hermann, Andreas Meinitzer, Dirk von Lewinski, Harald Sourij, and the EMMY Investigators
- Subjects
Clinical trial ,RCT ,Empagliflozin ,Heart failure ,Myocardial infarction ,Trimethylamine N-oxide ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Introduction The relationship between sodium glucose co-transporter 2 inhibitors (SGLT2i) and trimethylamine N-oxide (TMAO) following acute myocardial infarction (AMI) is not yet explored. Methods In this secondary analysis of the EMMY trial (ClinicalTrials.gov registration: NCT03087773), changes in serum TMAO levels were investigated in response to 26-week Empagliflozin treatment following an AMI compared to the standard post-MI treatment. Additionally, the association of TMAO changes with clinical risk factors and cardiorenal biomarkers was assessed. Results The mean age of patients (N = 367) was 57 ± 9 years, 82% were males, and 14% had type 2 diabetes. In the Empagliflozin group, the median TMAO value was 2.62 µmol/L (IQR: 1.81) at baseline, 3.74 µmol/L (2.81) at 6 weeks, and 4.20 µmol/L (3.14) at 26 weeks. In the placebo group, the median TMAO value was 2.90 µmol/L (2.17) at baseline, 3.23 µmol/L (1.90) at 6 weeks, and 3.35 µmol/L (2.50) at 26 weeks. The serum TMAO levels increased significantly from baseline to week 6 (coefficient: 0.233; 95% confidence interval 0.149–0.317, p
- Published
- 2023
- Full Text
- View/download PDF